vs

Side-by-side financial comparison of AMERICOLD REALTY TRUST (COLD) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.

EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $643.1M, roughly 1.4× AMERICOLD REALTY TRUST). EXACT SCIENCES CORP runs the higher net margin — -9.8% vs -13.7%, a 4.0% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs -0.7%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $-12.2M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs -0.6%).

Americold Realty Trust, Inc. is an American temperature controlled warehousing and transportation company based in Atlanta, Georgia, United States. It is in the business of modern commercialized temperature controlled warehousing for the storage of perishable goods via a cold chain, one of the forms of food preservation. Americold is the 2nd largest temperature-controlled warehousing and distribution services provider in the world.

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

COLD vs EXAS — Head-to-Head

Bigger by revenue
EXAS
EXAS
1.4× larger
EXAS
$878.4M
$643.1M
COLD
Growing faster (revenue YoY)
EXAS
EXAS
+23.8% gap
EXAS
23.1%
-0.7%
COLD
Higher net margin
EXAS
EXAS
4.0% more per $
EXAS
-9.8%
-13.7%
COLD
More free cash flow
EXAS
EXAS
$132.6M more FCF
EXAS
$120.4M
$-12.2M
COLD
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
-0.6%
COLD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
COLD
COLD
EXAS
EXAS
Revenue
$643.1M
$878.4M
Net Profit
$-88.3M
$-86.0M
Gross Margin
31.3%
70.1%
Operating Margin
-10.8%
-9.4%
Net Margin
-13.7%
-9.8%
Revenue YoY
-0.7%
23.1%
Net Profit YoY
-143.9%
90.1%
EPS (diluted)
$-0.31
$-0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COLD
COLD
EXAS
EXAS
Q4 25
$643.1M
$878.4M
Q3 25
$649.0M
$850.7M
Q2 25
$635.1M
$811.1M
Q1 25
$613.7M
$706.8M
Q4 24
$647.4M
$713.4M
Q3 24
$660.4M
$708.7M
Q2 24
$645.6M
$699.3M
Q1 24
$651.4M
$637.5M
Net Profit
COLD
COLD
EXAS
EXAS
Q4 25
$-88.3M
$-86.0M
Q3 25
$-11.4M
$-19.6M
Q2 25
$1.5M
$-1.2M
Q1 25
$-16.4M
$-101.2M
Q4 24
$-36.2M
$-864.6M
Q3 24
$-3.7M
$-38.2M
Q2 24
$-64.1M
$-15.8M
Q1 24
$9.7M
$-110.2M
Gross Margin
COLD
COLD
EXAS
EXAS
Q4 25
31.3%
70.1%
Q3 25
29.3%
68.6%
Q2 25
30.9%
69.3%
Q1 25
31.1%
70.8%
Q4 24
29.7%
69.0%
Q3 24
29.6%
69.4%
Q2 24
31.0%
69.8%
Q1 24
30.3%
70.0%
Operating Margin
COLD
COLD
EXAS
EXAS
Q4 25
-10.8%
-9.4%
Q3 25
2.6%
-3.0%
Q2 25
5.9%
-0.3%
Q1 25
3.6%
-13.6%
Q4 24
-1.8%
-122.8%
Q3 24
4.6%
-5.6%
Q2 24
9.8%
-3.8%
Q1 24
6.4%
-16.7%
Net Margin
COLD
COLD
EXAS
EXAS
Q4 25
-13.7%
-9.8%
Q3 25
-1.8%
-2.3%
Q2 25
0.2%
-0.1%
Q1 25
-2.7%
-14.3%
Q4 24
-5.6%
-121.2%
Q3 24
-0.6%
-5.4%
Q2 24
-9.9%
-2.3%
Q1 24
1.5%
-17.3%
EPS (diluted)
COLD
COLD
EXAS
EXAS
Q4 25
$-0.31
$-0.45
Q3 25
$-0.04
$-0.10
Q2 25
$0.01
$-0.01
Q1 25
$-0.06
$-0.54
Q4 24
$-0.12
$-4.69
Q3 24
$-0.01
$-0.21
Q2 24
$-0.23
$-0.09
Q1 24
$0.03
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COLD
COLD
EXAS
EXAS
Cash + ST InvestmentsLiquidity on hand
$136.9M
$964.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.9B
$2.4B
Total Assets
$8.1B
$5.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COLD
COLD
EXAS
EXAS
Q4 25
$136.9M
$964.7M
Q3 25
$33.3M
$1.0B
Q2 25
$101.4M
$858.4M
Q1 25
$38.9M
$786.2M
Q4 24
$47.7M
$1.0B
Q3 24
$61.3M
$1.0B
Q2 24
$44.2M
$946.8M
Q1 24
$59.2M
$652.1M
Stockholders' Equity
COLD
COLD
EXAS
EXAS
Q4 25
$2.9B
$2.4B
Q3 25
$3.0B
$2.5B
Q2 25
$3.1B
$2.5B
Q1 25
$3.2B
$2.4B
Q4 24
$3.3B
$2.4B
Q3 24
$3.4B
$3.2B
Q2 24
$3.4B
$3.2B
Q1 24
$3.6B
$3.1B
Total Assets
COLD
COLD
EXAS
EXAS
Q4 25
$8.1B
$5.9B
Q3 25
$8.1B
$5.9B
Q2 25
$8.1B
$5.8B
Q1 25
$7.8B
$5.7B
Q4 24
$7.7B
$5.9B
Q3 24
$7.9B
$6.7B
Q2 24
$7.8B
$6.7B
Q1 24
$7.8B
$6.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COLD
COLD
EXAS
EXAS
Operating Cash FlowLast quarter
$130.2M
$151.7M
Free Cash FlowOCF − Capex
$-12.2M
$120.4M
FCF MarginFCF / Revenue
-1.9%
13.7%
Capex IntensityCapex / Revenue
22.1%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-217.2M
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COLD
COLD
EXAS
EXAS
Q4 25
$130.2M
$151.7M
Q3 25
$78.9M
$219.9M
Q2 25
$120.3M
$89.0M
Q1 25
$30.2M
$30.8M
Q4 24
$162.6M
$47.1M
Q3 24
$50.6M
$138.7M
Q2 24
$136.7M
$107.1M
Q1 24
$62.0M
$-82.3M
Free Cash Flow
COLD
COLD
EXAS
EXAS
Q4 25
$-12.2M
$120.4M
Q3 25
$-65.4M
$190.0M
Q2 25
$-57.4M
$46.7M
Q1 25
$-82.3M
$-365.0K
Q4 24
$57.4M
$10.7M
Q3 24
$-44.5M
$112.6M
Q2 24
$73.3M
$71.2M
Q1 24
$16.2M
$-120.0M
FCF Margin
COLD
COLD
EXAS
EXAS
Q4 25
-1.9%
13.7%
Q3 25
-10.1%
22.3%
Q2 25
-9.0%
5.8%
Q1 25
-13.4%
-0.1%
Q4 24
8.9%
1.5%
Q3 24
-6.7%
15.9%
Q2 24
11.4%
10.2%
Q1 24
2.5%
-18.8%
Capex Intensity
COLD
COLD
EXAS
EXAS
Q4 25
22.1%
3.6%
Q3 25
22.2%
3.5%
Q2 25
28.0%
5.2%
Q1 25
18.3%
4.4%
Q4 24
16.3%
5.1%
Q3 24
14.4%
3.7%
Q2 24
9.8%
5.1%
Q1 24
7.0%
5.9%
Cash Conversion
COLD
COLD
EXAS
EXAS
Q4 25
Q3 25
Q2 25
78.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
6.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

COLD
COLD

Warehouse Services$269.0M42%
Warehouse Rent And Storage$199.9M31%
Other Facilities Costs$60.0M9%
Transportation Segment$48.3M8%
Power$34.7M5%
Transportation$22.0M3%
Third Party Managed Segment$9.5M1%
Third Party Managed$2.4M0%

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

Related Comparisons